Michael Turner

Hermes GPE LLP (Hermes GPE), a subsidiary of Hermes Fund Managers Ltd founded in 1983. The firm is headquartered in London with additional offices in Singapore and New York.

GHO Capital Partners LLP (GHO Capital Partners) is a private equity firm founded in 2014 by Mireille G. Gillings, Dennis B. Gillings, Alan Browning MacKay, Michael Irvine Mortimer and Andrea Ponti. The firm is headquartered in London, United Kingdom.

Quotient Sciences Ltd. provides early stage drug development services. The firm offers formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industries. The company was founded in 1990 and is headquartered in Ruddington, the United Kingdom.

3i Private Equity is a private equity firm, founded in 1945. The firm is headquartered in London, United Kingdom with additional offices around the world.

Watch Bidco Ltd. functions as an investment holding British company. The private company is based in Ruddington, UK.

Part of Watch Topco Ltd., Watch Midco 1 Ltd. functions as an investment holding British company. The company is based in Ruddington, UK and was founded in 2015.

Part of Watch Topco Ltd., Quotient Sciences Holdings Ltd. is an investment holding British company. The company is based in Nottingham, UK. Quotient Sciences Holdings was founded in 2015.

Quotient Sciences (Reading) Ltd. develops preclinical and early phase formulations and manufactures clinical trials materials. It engages in optimization of drug substance physical forms (salt, polymorphs and co-crystals), the development of preclinical and early phase formulations and the manufacture of clinical trial materials. The company was founded by Graham Buckton in January 2000 and is headquartered in Reading, the United Kingdom.

Mint Holdco UK Ltd. operates as a financial services holding firm. The company was founded on December 11, 2019 and is headquartered in Fareham, the United Kingdom.

Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022.